Drug
Aro Apoc3
Aro Apoc3: highest development phase Phase 2, developed by Arrowhead Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARO-APOC3 NCT04720534 | Phase 2 | Severe Hypertriglyceridemia |
| ARO-APOC3 NCT04998201 | Phase 2 | Mixed Dyslipidemia |
Latest
No recent events.
Follow Aro Apoc3 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.